Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)

NCT05544032 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-10-08

No results posted yet for this study

Summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Conditions

  • Chronic Graft Vs. Host Disease

Interventions

DRUG

axatilimab

Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks

Sponsors & Collaborators

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544032 on ClinicalTrials.gov